AT-RISK AREAS

Chikungunya is a rising global health threat

Chikungunya is a global health threat with more than ¾ of the world’s population estimated to live in areas at risk of the disease.

Areas of greatest risk for travellers are the Americas, parts of Africa, and Southeast Asia.

  • As of 2024, the majority of countries reporting the highest number of cases are located in South and Central America, including, Brazil (317,563), Paraguay (3034), Argentina (632), and Bolivia (346).

AREAS AT RISK FOR CHIKUNGUNYA (LAST 5 YEARS)

ixchiq_dtc_maple_leaf_icon

A SURGE IN CANADIAN CHIKUNGUNYA INFECTIONS HAS BEEN LINKED TO THE VIRUS ENTERING INTO THE CARIBBEAN AND EXPANDING INTO THE AMERICAS.

Current outbreak
of chikungunya
Maldives (as of
May 28, 2024)

Evidence of
transmission within
the last 5 years

MY PLAN OF ACTION
IXCHIQ™ is a vaccine for intramuscular injection for use in individuals 18 years of age and older to help protect against chikungunya virus. As with all vaccines, 100% protection is not guaranteed. IXCHIQ™ does not treat an infection or its complications once they develop. IXCHIQ™ does not protect against other diseases transmitted by mosquitoes. You should still protect yourself from mosquito bites even if you have been vaccinated with IXCHIQ™. Talk to your healthcare professional to see if IXCHIQ™ is right for you.
VALNEVA Canada Inc.
600-3535, Saint-Charles Blvd.
Kirkland (Montreal), Quebec H9H 5B9
© 2024 VALNEVA Canada Inc.
All trademarks used under license.
CA-IXC-2400011E
VALNEVA Canada Inc.
600-3535, Saint-Charles Blvd.
Kirkland (Montreal), Quebec
H9H 5B9
© 2024 VALNEVA Canada Inc.
All trademarks used under license.
CA-IXC-2400009E
WANT TO STAY UP TO DATE? SIGN UP TO RECEIVE ALL THE LATEST INFORMATION FROM VALNEVA ABOUT IXCHIQ™




    REPORT A POSSIBLE ADVERSE DRUG REACTION
    * Required field
    Stay connected
    Sign up to receive all the latest information from Valneva about IXCHIQ™.
    STAY CONNECTED